Navigation Links
Misonix Reports Nine Months Fiscal 2013 Financial Results
Date:5/9/2013

ntinued to invest in research and development, sales, marketing and customer support capabilities.

For the nine months, the Company reported a net loss of $1.1 million, or $(0.16) per share, which included income from discontinued operations of $181,800, or $0.03 per share, compared to a net loss of $78,488, or $(0.01) per share in the comparable nine month period of 2012, which included a net loss from discontinued operations of $369,424, and a gain from the sale of discontinued operations of $1.1 million, totaling net income from discontinued operations of $773,966, or $0.11 per share.

Michael A. McManus, Jr., president and chief executive officer of Misonix, commented, "For the nine months of fiscal 2013, we had a very positive impact from the recurring revenue component of our business – disposables sales of our flagship BoneScalpel, SonicOne and SonaStar products. Revenue from the sale of disposables totaled $4.8 million, or 43% of total sales. On a sequential basis, BoneScalpel disposables revenue and unit sales increased 48% and 44%, respectively, in the third quarter from the second quarter. 

"Disposable revenue is significant in that hospitals across the country are increasingly evaluating medical devices for efficacy and cost effectiveness and have distinctly lengthened the domestic sales cycle. The resulting delay in completing instrument sales or placements is now being increasingly offset by our growing recurring revenue component. In addition, we are now benefitting to a greater degree by expanded royalty income and license fees. We have developed a significant portfolio of intellectual property and are pleased to see that it is generating increasing royalty revenue, predominantly from Covidien, as evidenced by the $1.8 million earned in the nine months of 2013 compared to the $462,000 earned in the comparable nine months of 2012."

"While the dynamics in the healthcare markets appear to be changing, we are well
'/>"/>

SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Misonix Announces New Distribution Agreement For Denmark
2. Misonix Reports Financial Results for First Half of Fiscal 2013
3. Misonix Presents at MicroCapClub Invitational
4. Misonix Terminates Distribution Agreement With Aesculap
5. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
6. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
7. Misonix Product Featured At Neurosurgery Congress
8. Misonix Adds 6 Spine Sales Agencies In The U.S.
9. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
10. Misonix Inks New Distribution Agreement For Croatia And Slovenia
11. Misonix And Soelim Create New Distribution Alliance For South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) ... "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with the ... provides an update for shareholders detailing why a "YES" vote ... Dear Shareholders, As we reflect upon the ...
(Date:1/23/2015)... Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), ... extracorporeal cytokine adsorber to reduce deadly inflammation in ... of $385,642, net of transaction costs, in non-dilutive ... Business Tax Certificate Transfer Program sponsored by the ...
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Data Presented at the 11th International Myeloma Workshop ... 29, 2007,/PRNewswire/ -- The International Myeloma Foundation (IMF) ... myeloma patients, families, researchers and physicians -- today,said ... Workshop in Greece demonstrate improved survival for a ...
... 2007 - The drug most,commonly used to arrest ... common treatment to cause mild to serious side,effects ... researchers at,Lucile Packard Children's Hospital and Stanford University ... effectiveness,of the two drugs appears similar, physicians should ...
Cached Medicine Technology:The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 2Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 3Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 4
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... an effort to further promote visibility and adoption of the ... made AMA journals available via its subscription services, EBSCO will ... , Long known as both a subscription agency ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... seeking consular access to Mohammed Haneef, currently detained in ... ,On Tuesday the Indian External Affairs Ministry ... concern over the treatment of Haneef. ,"The ... Australian Government that Dr Mohamed Haneef should be treated ...
... medical journal of the American Academy of Neurology, children who ... kids , grades in foreign language are the most affected ... good grades. , Researchers say this is the ... survivors have been reported. ,These results will help ...
... 31, the Atlanta lawyer who traveled around with TB infection, ... ,Speaker raised an international health scare when he ... disease. Andrew Speaker was diagnosed in May with extensively drug ... in March by the U.S. Centers for Disease Control and ...
... seek to position themselves as great champions of environment. ... Flannery, the Australian of the Year Professor who has ... to come out with specific proposals instead of resorting ... also faulted the John Howard government's move to allocate ...
... to the high incidence of lower respiratory tract lung ... and colleagues collected data on respiratory health and indoor ... of age in the Baffin Region of Nunavut. ... significantly associated with indoor carbon dioxide levels and occupancy. ...
... sedated at the time he was murdered, because a high ... the boy's system. It was also found that Chris had ... killed his wife and young son last month and hanged ... chief medical examiner for the state with the Georgia Bureau ...
Cached Medicine News:Health News:Brain Tumor Children Poor Performance in Schools 2Health News:TB Traveler Underwent Surgery to Remove Infected Lung Tissue 2Health News:Subsidize Solar Water Heaters for Homes, Expert Tells Australian Government 2Health News:Poor Ventilation may Cause Lung Disorders Inn Inuit Children 2Health News:Wrestler Chris Benoits Son was Sedated - Says Investigators 2
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
Medicine Products: